<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03955367</url>
  </required_header>
  <id_info>
    <org_study_id>PUMCH-EFI</org_study_id>
    <nct_id>NCT03955367</nct_id>
  </id_info>
  <brief_title>Pelvic RT Versus Prophylactic Extended-field RT in Patients With Cervical Cancer</brief_title>
  <official_title>Pelvic Irradiation Versus Prophylactic Extended-field Irradiation in Selected Patients With Cervical Cancer Treated With Concurrent Chemoradiotherapy: A Multicenter, Open-label, Randomized, Phase 3 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cangzhou Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tumor Hospital of Gansu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harbin Medical University Third Affiliated Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guizhou Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China-Japan Union Hospital, Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jilin Provincial Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangsu Cancer Institute &amp; Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The 940th Hospital of Joint Logistics Support Force，PLA.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Hospital of Benxi Iron &amp; Steel Industry Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Inner Mongolia Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Hospital of Ningxia Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Obstetrics and Gynecology Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tangshan People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhongnan Hospital of Wuhan University &amp; Second Clinical Hospital of Wuhan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital of Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Tumor Hospital of Xinjiang Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Cancer Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>the Seventh Medical Center of PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shengjing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xi’an Gaoxin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Second University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the value of prophylactic extended-field irradiation (EFI), we conduct a
      randomized clinical trial to compare the efficacy and toxicity of pelvic irradiation and
      prophylactic EFI in selected patients with cervical cancer treated with definitive concurrent
      chemoradiotherapy. External beam radiation therapy is delivered with intensity-modulated
      radiation therapy (IMRT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open-label, phase III randomized clinical trial. Cervical cancer
      patients without evidence of para-aortic metastatic lymph nodes (MLNs) and with at least one
      of the following characteristics are included in the present study: (a) Number of pelvic MLNs
      ≥ 2; (b)Short diameter of pelvic MLNs ≥ 1.5cm; (c)Pelvic wall involvement. Patients are
      randomly assigned to pelvic irradiation group and prophylactic EFI group. Patients in pelvic
      irradiation group receive pelvic irradiation, intracavitary brachytherapy and concurrent
      chemotherapy. Patients in prophylactic EFI group receive irradiation for pelvis and
      para-aortic lymph nodes region, intracavitary brachytherapy and concurrent chemotherapy. The
      upper border of clinical target volume (CTV) is at the level of renal vessels for patients in
      prophylactic EFI group. A dose of 45-50.4 Gy is delivered to CTV with IMRT in both groups.
      Patients receive cisplatin based concurrent chemotherapy (single cisplatin or cisplatin plus
      paclitaxel). The primary endpoint is progression-free survival.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 17, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>3-year</time_frame>
    <description>Progression-free survival is defined as the time from randomization to disease progression or death from any cause, whichever is first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3-year</time_frame>
    <description>Overall survival is calculated from randomization to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant failure-free survival</measure>
    <time_frame>3-year</time_frame>
    <description>Distant failure-free survival is defined as the time from randomization to distant metastasis or death from any cause, whichever is first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Para-aortic lymph nodes failure rate</measure>
    <time_frame>3-year</time_frame>
    <description>The incidence of para-aortic lymph nodes failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity evaluated with CTCAE 5.0</measure>
    <time_frame>From the start of treatment to 3 months after treatment.</time_frame>
    <description>Evaluated with CTCAE 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late toxicity evaluated with Radiation Therapy Oncology Group (RTOG)/EORTC late radiation morbidity scoring scheme</measure>
    <time_frame>3-year</time_frame>
    <description>Evaluated with Radiation Therapy Oncology Group (RTOG)/EORTC late radiation morbidity scoring scheme</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">638</enrollment>
  <condition>Uterine Cervical Neoplasms</condition>
  <arm_group>
    <arm_group_label>Pelvic Irradiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive concurrent chemoradiotherapy. The CTV includes the gross tumor, cervix, uterus, parametrium, upper part of the vagina, and pelvic lymph nodes regions. The upper border of CTV is at the level of aortic bifurcation. A dose of 45-50.4Gy is delivered to CTV with IMRT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prophylactic EFI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive concurrent chemoradiotherapy. The CTV includes the gross tumor, cervix, uterus, parametrium, upper part of the vagina, pelvic lymph nodes regions and para-aortic lymph nodes region. The upper border of CTV is at the level of renal vessels. A dose of 45-50.4Gy is delivered to CTV with IMRT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Prophylactic extended-field Irradiation</intervention_name>
    <description>CTV covers pelvis and para-aortic lymph nodes region.</description>
    <arm_group_label>Prophylactic EFI</arm_group_label>
    <other_name>Prophylactic radiotherapy for para-aortic lymph nodes region</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Pelvic irradiation</intervention_name>
    <description>CTV covers pelvis.</description>
    <arm_group_label>Pelvic Irradiation</arm_group_label>
    <other_name>Pelvic radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intracavitary brachytherapy</intervention_name>
    <description>The total dose delivered to point A or high-risk CTV is ≥80Gy. For patients with larger-volume cervical tumor, the total dose is ≥85Gy.</description>
    <arm_group_label>Pelvic Irradiation</arm_group_label>
    <arm_group_label>Prophylactic EFI</arm_group_label>
    <other_name>Brachytherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Concurrent chemotherapy</intervention_name>
    <description>Cisplatin based concurrent chemotherapy, including cisplatin as a single agent or cisplatin plus Paclitaxel.</description>
    <arm_group_label>Pelvic Irradiation</arm_group_label>
    <arm_group_label>Prophylactic EFI</arm_group_label>
    <other_name>Chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must be informed of the investigational nature of this study and give written
             informed consent with 30 days before treatment.

          2. Age ≥18 years and ≤ 70 years.

          3. Patients with newly histologically confirmed cervical cancer, including squamous cell
             carcinoma, adenocarcinoma and adenosquamous carcinoma, et al.

          4. No evidence of para-aortic metastatic lymph nodes (MLNs) on CT, MRI or positron
             emission tomograph (PET)/CT.*

          5. No evidence of distant metastasis (FIGO stage IVB).

          6. At least meet one of the following characteristics:

               1. Number of pelvic MLNs ≥ 2;

               2. Short diameter of pelvic MLNs ≥ 1.5cm; *

               3. Parametrial involvement to the pelvic wall ＃.

          7. Satisfactory performance: Eastern Cooperative Oncology Group (ECOG) score ≥ 2.

          8. Adequate marrow: neutrophile granulocyte count ≥1.5*10^9/L, hemoglobin ≥ 80 g/L,
             platelet count ≥100*10^9/L.

          9. Normal liver and kidney function: Creatinine (Cr) &lt; 1.5 mg/dl, Alanine
             Aminotransferase (ALT), Aspartate Aminotransferase (AST) &lt; 2*upper limit of normal
             (ULN).

               -  MLNs refer to positive lymph nodes confirmed by PET/CT or lymph nodes with short
                  diameter ≥ 1 cm on CT or MRI.

                    -  Parametrial involvement to the pelvic wall is diagnosed with gynecological
                       examination or MRI;

        Exclusion Criteria:

          1. With common iliac MLNs.

          2. Tumor extended to the lower third of the vagina.

          3. Tumor spread to mucosa of the bladder or rectum.

          4. Prior surgery (including pelvic or para-aortic lymph nodes resection, except for tumor
             biopsy), radiotherapy or chemotherapy to primary tumor or nodes.

          5. Prior malignancy.

          6. History of previous radiotherapy to the abdomen or pelvis.

          7. Pregnancy or lactation.

          8. Active inflammatory bowel disease, or history of severe stomach or duodenal ulcer.

          9. Active infection with fever.

         10. Patients with unacceptable risk that intracavitary brachytherapy can not be conducted.

         11. Any severe disease which may bring unacceptable risk or affect the compliance of the
             trial, for example, unstable cardiac disease requiring treatment, renal disease,
             chronic hepatitis, diabetes with poor control, and emotional disturbance.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ke Hu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ke Hu</last_name>
    <phone>+86-01069155487</phone>
    <email>huk@pumch.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ke Hu, MD</last_name>
      <phone>010-69155482</phone>
      <email>huk@pumch.cn</email>
    </contact>
    <contact_backup>
      <last_name>Weiping Wang, PhD</last_name>
      <phone>010-69155483</phone>
      <email>jluwangweiping@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zi Liu</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Wang W, Liu X, Meng Q, Zhang F, Hu K. Prophylactic Extended-Field Irradiation for Patients With Cervical Cancer Treated With Concurrent Chemoradiotherapy: A Propensity-Score Matching Analysis. Int J Gynecol Cancer. 2018 Oct;28(8):1584-1591. doi: 10.1097/IGC.0000000000001344.</citation>
    <PMID>30153215</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 11, 2019</study_first_submitted>
  <study_first_submitted_qc>May 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2019</study_first_posted>
  <last_update_submitted>August 5, 2019</last_update_submitted>
  <last_update_submitted_qc>August 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Ke Hu</investigator_full_name>
    <investigator_title>Vice director of Radiation Oncology Department</investigator_title>
  </responsible_party>
  <keyword>Uterine Cervical Neoplasms</keyword>
  <keyword>Extended-field irradiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

